Table 4 Clinical and analytical factors associated with EPCs in patients with HIV infection and the relationship with subclinical atherosclerosis.
From: Evaluation of endothelial function and subclinical atherosclerosis in patients with HIV infection
Very Early EPCs | Early EPCs | |||||
|---|---|---|---|---|---|---|
CD34 + 309 + 133 + | CD34 + 309 + 133- | |||||
n | cells/µl (Mean ± SD) | P valuea | cells/µl (Mean ± SD) | P valuea | ||
HIV analytical related parameters | ||||||
Nadir CD4 (cells/ μl) | < 350 | 61 | 0.335 ± 0.606 | 0.144 ± 0.218 | ||
≥ 350 | 16 | 0.913 ± 2.214 | 0.07 | 0.654 ± 1.786 | 0.03 | |
Zenith VL (copies/ml) | < 200,000 | 42 | 0.554 ± 1.30 | 0.313 ± 0.963 | ||
≥ 200,000 | 35 | 0.123 ± 0.17 | 0.20 | 0.059 ± 0.076 | 0.31 | |
HIV clinical related parameters | ||||||
Time of infection (years) | < 20 | 32 | 0.318 ± 0.578 | 0.156 ± 0.245 | ||
≥ 20 | 45 | 0.666 ± 0.245 | 0.28 | 0.397 ± 0.284 | 0.33 | |
Time of HAART (months) | < 200 | 41 | 0.291 ± 0.396 | 0.152 ± 0.220 | ||
≥ 200 | 36 | 0.682 ± 1.711 | 0.21 | 0.381 ± 1.281 | 0.34 | |
> 1 year from diagnosis to HAART | Yes | 41 | 0.308 ± 0.598 | 0.373 ± 1.239 | ||
No | 36 | 0.639 ± 1.583 | 0.254 | 0.153 ± 0.237 | 0.31 | |
Subclinical atheroesclerosis | ||||||
IMT | < 0,9 | 54 | 0.460 ± 1.285 | 0.298 ± 1.000 | ||
≥ 0,9 | 23 | 0.445 ± 0.787 | 0.95 | 0.143 ± 1.286 | 0.30 | |
CACS | < 10 AU | 56 | 0.388 ± 0.640 | 0.176 ± 0.241 | ||
≥ 10AU | 21 | 0.622 ± 1.913 | 0.58 | 0.437 ± 1.540 | 0.44 | |
